publication date: Jul. 29, 2016

Conversation with The Cancer Letter

Pellini: Data Sharing Central to Mission At Foundation Medicine


Making data broadly available to clinicians and researchers has always been a part of the mission for Foundation Medicine Inc., said Michael Pellini, the company’s CEO.

“We are proud to say the data that we contributed represents an important part of the GDC in terms of its sheer size,” said Pellini, discussing FMI’s decision to contribute 18,000 de-identified patient cases to NCI’s Genomic Data Commons.

Pellini spoke with Matthew Ong, a reporter with The Cancer Letter.


Matthew Ong: What is Foundation Medicine best known for?

Michael Pellini: In very simple terms, we are a molecular information company that does two things extraordinarily well: the first is we extract the relevant molecular drivers from a patient’s tumor, and number two, we contextualize that information and deliver it back to our clients in a way that they can utilize it either for patient care or for drug development.

Foundation Medicine coined the phrase molecular information company going back about five or six years ago. Our aim was to do two things that were critically important for cancer care in the modern era and that would be extremely difficult for others to replicate. We receive tissue samples from oncologists and pathologists working in academic cancer centers and community setting across the country and around the world. We also work with dozens of pharmaceutical companies. When we receive the tissue, we run it through our proprietary platform, which includes next generation sequencing, and we call this process comprehensive genomic profiling. We extract the relevant genomic drivers from the patient’s tumor, but that’s only step one.

The second part of it … Continue reading 42-30 Pellini: Data Sharing Central to Mission At Foundation Medicine

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.